VOLITIONRX LTD Stock News

Vanguard Group Inc. reduced its stake in VolitionRx Limited (NYSEAMERICAN:VNRX) by 21.4% during the 2nd quarter, Holdings Channel.com reports. The firm owned 499,085 shares of the medical research companys stock after selling 136,039 shares during the period. Vanguard Group Inc.s holdings in VolitionRx were worth $1,643,000 as of its most recent filing with the Securities [] The post Vanguard Group Inc. Has $1.64 Million Position in VolitionRx Limited (NYSEAMERICAN:VNRX) appeared first on ETF Daily News .

VolitionRx Limited (NYSEAMERICAN:VNRX) Zacks Investment Research decreased their FY2021 earnings per share (EPS) estimates for VolitionRx in a report released on Monday, November 22nd. Zacks Investment Research analyst S. Ralston now forecasts that the medical research company will earn ($0.50) per share for the year, down from their previous forecast of ($0.42). Zacks Investment []

VolitionRx Limited (NYSEAMERICAN:VNRX) CEO Salvatore Thomas Butera purchased 10,000 shares of VolitionRx stock in a transaction on Tuesday, November 16th. The stock was acquired at an average cost of $4.02 per share, for a total transaction of $40,200.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this []

AUSTIN, Texas, Nov. 8, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Thursday, November 11, at 8:00 a.m. Eastern time to

Strong balance sheet with approximately $27.9 million in cash and cash equivalents Strengthened the Company's veterinary leadership team to drive commercial focus Expanded the Company's intellectual p

AUSTIN, Texas, Aug. 4, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Thursday, August 12, at 8:00 a.m. Eastern time to di

AUSTIN, Texas, July 22, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to h

Secured strongest-ever balance sheet with approximately $33.1 million in cash Strengthened the Company's leadership team to drive commercial focus Expanded the Company's intellectual property portfoli

AUSTIN, Texas, March 31, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to

AUSTIN, Texas, March 30, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to

AUSTIN, Texas, March 29, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to

Launched first product, the Nu.Q® Vet Cancer Screening Test and recorded first revenue from sales of a commercial product Engaged Diagnostic Oncology CRO LLC to conduct U.S. regulatory clinical trial

AUSTIN, Texas, March 17, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to

AUSTIN, Texas, March 16, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Tuesday, March 23, at 8:00 a.m. Eastern time to d

Volition is one of the sponsors for the upcoming Benzinga Global Small Cap Conference set to take place on December 8-9, 2020. Given the growing population, it is expected that the number of cancer di